Kimberly-Clark Sees 14% Spike on Stocktwits Amid Kenvue Deal Controversy

Kimberly-Clark's stock has seen a 14% spike in watchlist additions on Stocktwits following its $48.7 billion Kenvue acquisition. Investors are divided over the deal due to concerns about Kenvue's Tylenol pain reliever causing a higher risk of autism. Certain brokerages have reduced their price targets, with 12 out of 18 analysts covering the stock having a "Hold" rating and five rating it "Buy" or higher.